MTOR and hepatocellular carcinoma: While there is no standard post-transplant immunosuppression protocol for HCC, a current consensus recommends using steroid-free immunosuppression and decreasing CNI exposure by incorporating mTOR inhibitors due to their anti-tumor potential [132].